RLMD RELMADA THERAPEUTICS, INC. Insider Trading

CFO Shenouda Maged buys 11,665 shares of RLMD at $4.12; stock now at $4.50 (+13.9% in 30d), but company reports -35.4% revenue decline YoY.

Shenouda Maged, the Chief Financial Officer, purchased 11,665 shares at $4.12 on 2025-12-15, bringing his holdings to 800,000 shares (an increase of 1.5%). The purchase occurs in a context of strong recent momentum: the stock has gained 13.9% in the last 30 days and 198.0% over the past 90 days, and is currently trading at $4.50. However, this near-highs purchase (stock at -0.2% from 52-week high) occurs while the company faces significant operational headwinds: annual revenue has declined 35.4% year-over-year, the company posted a net loss of $-10.1M in the latest quarter, and full-year results show the company is unprofitable. Maged's same-ticker history shows 3 of 4 prior buys at RLMD produced positive 90-day returns, including his most recent purchase on 2025-11-05 which returned +92.7% at the 30-day mark; however, his earlier buy on 2024-09-11 subsequently declined 84.1% over 90 days, indicating timing accuracy is inconsistent at this ticker. The divergence between strong price action, insider buying by the CFO, and deteriorating fundamentals merits attention to whether near-term momentum masks underlying business stress.

CEO Traversa buys 27,500 RLMD shares at $4.12; 4 of 4 prior same-ticker purchases were well-timed, with 90d returns of +92.7% to +593.6%.

Sergio Traversa, the CEO, purchased 27,500 shares at $4.12 on 2025-12-15 for $113,300.00, bringing his holdings to 1.30M shares. His same-ticker trade history at RLMD is exceptional: four prior purchases (on 2025-08-26, 2025-08-27, 2025-08-28, and 2025-11-05) all registered positive 90-day returns, with outcomes ranging from +92.7% to +593.6%, and the earlier three clustered in August all exceeded +466% at the 90-day mark. This pattern—a 100% well-timed track record at this ticker across measurable intervals—stands in sharp contrast to the company's fundamentals: annual revenue declined 35.4%, the company posted a net loss of $-10.1M in its most recent full fiscal year, and the latest quarter generated only $682.00 in revenue. The buy occurs at $4.12, well within the 52-week range ($0.25–$4.51) and currently 0.2% below the 52-week high of $4.51, after a 30-day surge of +13.9% and a 90-day spike of +198.0%. The repeated, consistently well-timed purchases at depressed valuations amid deteriorating financials warrant close monitoring of what information or operational catalyst the CEO may be observing.

CFO Shenouda Maged buys 500,000 shares of RLMD at $2.20; holdings rise 173.4%; company unprofitable with -35.4% annual revenue decline.

Shenouda Maged, CFO of Relmada Therapeutics, purchased 500,000 shares at $2.20 on 2025-11-05, increasing his holdings from 288,335 shares to 788,335 shares (+173.4%). This is a material open-market acquisition of $1,100,000.00. The timing follows strong near-term momentum: the stock is up +31.2% over 30 days and +344.3% over 90 days from the transaction date. However, this buy occurs against a backdrop of deteriorating fundamentals: the company posted net income of $-9,866,442.00 (negative) in its most recent full fiscal year, with annual revenue declining -35.4% year-over-year and latest quarterly revenue of only $682.00. At Relmada specifically, Maged's prior five trades show a 60% timing success rate (3 of 5 well-timed at the 90-day mark), with recent May 2025 buys posting +26.8% to +37.4% 90-day returns; earlier 2024 buys posted steep 90-day declines of -82.4% and -84.1%. The current purchase is concurrent with a cluster of three other insider buys within 14 days, suggesting coordinated appetite despite the company's negative earnings trajectory.

RLMD CAO/COO Ence Chuck bought 136,000 shares at $2.20 (+50.8% of prior holdings); 3 other insiders also bought within 14 days

Ence Chuck, CAO and COO of Relmada Therapeutics, purchased 136,000 shares at $2.20 on 2025-11-05, expanding his holdings from 267,931 shares to 403,931 shares—a 50.8% increase. This transaction is part of a cluster buy pattern in which 3 other insiders also purchased shares within the past 14 days, suggesting coordinated confidence at current valuations. His prior trades at RLMD show mixed near-term returns—two of four prior buys achieved positive 90-day returns (+55.2% and +34.5% respectively)—though the company faces fundamental headwinds: annualized revenue of $682.00 latest quarter, a net loss of $-9,866,442.00 over the most recent full year, and annual revenue growth of -35.4%. The stock has risen 31.2% in the past 30 days and 344.3% over 90 days from depressed levels, leaving it 25.2% below its 52-week high of $3.49. The timing and scale of this buy relative to both recent price momentum and underlying profitability decline warrants careful review.

RLMD CEO Traversa buys 272,500 shares at $2.20 (11/5/25); 27.2% stake increase amid cluster buy; unprofitable firm with -35.4% revenue decline

CEO Sergio Traversa purchased 272,500 shares at $2.20 on 2025-11-05, increasing his holdings by 27.2% to 1,272,500 shares total—a significant concentration move by the company's chief executive. This buy occurs within a 14-day window when 3 other insiders also purchased, signaling a coordinated insider accumulation pattern. Relmada's fundamentals remain deeply concerning: the company reported quarterly revenue of $682.00, negative annual net income of $-9,866,442.00, and year-over-year revenue contraction of -35.4%, indicating ongoing operational distress. Traversa's prior trades at RLMD show measurable 90-day outcomes on 2 historical buys, both posting positive 90-day returns, though his broader cross-ticker track record is mixed (12 prior buys averaging -20.2% over 90 days with a 44.44% win rate), suggesting his timing ability at this specific ticker does not extrapolate to his general record.

COO Kelly Paul Edward buys 90,000 RLMD shares at $2.20; holdings rise to 502,295 shares (+21.8%); 3 other insiders also bought within 14 days

Kelly Paul Edward, COO, purchased 90,000 shares at $2.20 on 2025-11-05, increasing his holdings by 21.8% to 502,295 shares total. The transaction occurred within a broader cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated insider confidence at this price point. His same-ticker trade history is mixed—a May 2025 buy yielded +62.7% in 30 days and +41.1% in 90 days, while a September 2024 buy declined -82.3% by the 90-day mark—underscoring the volatility and unpredictability of timing outcomes in this stock. RLMD's fundamentals remain challenged: the company posted a $-9.9M net loss most recently and showed -35.4% annual revenue decline, despite the stock's recent 30-day surge of +31.2% from depressed levels. The cluster buy pattern warrants investor attention as a potential signal of management's view of intrinsic value, though the company's unprofitable status and negative revenue trajectory raise material questions about capital allocation discipline in a highly volatile biotech context.

Relmada CEO Traversa buys 265,976 shares across 3 days for $178,094.99; holdings jump +36.2% to 1,000,000 shares

Sergio Traversa, CEO of Relmada Therapeutics (unprofitable, -35.4% annual revenue decline, $25.9M market cap), executed 3 separate purchases totaling 265,976 shares for $178,094.99 at prices ranging from $0.62 to $0.74 on Aug 26–28, 2025. This increased his holdings by 36.2% from 734,024 to 1,000,000 shares, a material position expansion. The timing coincides with a 24.7% 30-day price run (+$0.53 from prior lows to current $0.78), though the stock remains -78.6% below its 52-week high of $3.64. Traversa's recent same-ticker purchase history shows mixed outcomes: his May 2025 buys achieved +25.7% to +55.7% 90-day returns, but earlier buys in September 2024 resulted in -82.5% and -84.3% declines. The concentrated three-day sequence and aggressive share accumulation in a micro-cap therapeutics company trading near its 52-week lows warrant close attention to company-specific catalysts or financial health signals that may have prompted this expansion.

COO Kelly Paul Edward buys 200,000 shares of RLMD at $0.43; stock now $0.60, but company posted -$17.6M net income with -35.4% revenue decline.

Kelly Paul Edward, Chief Operating Officer, purchased 200,000 shares (200.0K shares) at $0.43 on 2025-05-16, increasing his holdings by 94.2% to 412.3K shares. The purchase totaled $86.1K. However, the company faces significant financial headwinds: latest quarterly revenue stood at $682.00, full-year net income was -$17.6M, and annual revenue has declined 35.4% year-over-year. His prior buy at RLMD on 2024-09-09 returned +31.3% over 30 days but -82.3% over 90 days, establishing a pattern of initial gains followed by substantial losses at this ticker. The stock has recovered 107% over the past 30 days from depressed levels but remains 86.2% below its 52-week high of $4.36, and his cross-ticker track record shows a 0% win rate on 90-day outcomes despite one prior buy. The concurrent cluster of 3 other insider buys within 14 days warrants consideration as potential coordinated action, but set against deteriorating fundamentals and a company burning capital, this transaction signals distress rather than fundamental conviction.

CEO Traversa buys 350.0K shares in 3 transactions at $0.45–$0.56, averaging $0.50; holdings +91.1% to 734.0K shares amid stock -86.2% from 52-week high.

Sergio Traversa, CEO of Relmada Therapeutics, executed 3 separate open-market purchases totaling 350,000 shares for $174,712.70 between May 16–20, 2025, at prices ranging from $0.45 to $0.56, with a blended average of $0.50. This represents a 91.1% increase in his holdings to 734,024 shares. The stock has declined 86.2% from its 52-week high of $4.36 to a current price of $0.60, though it has gained 107.0% over the past 30 days and 82.9% over 90 days. At the same ticker, Traversa's prior 5 buys show a consistent pattern: 0 of 5 achieved positive 90-day returns, with declines ranging from -83.1% to -84.3% in the September 2024 cluster. The company is unprofitable with a net loss of $17,559,465 over its most recent full fiscal year, annual revenue growth of -35.4%, and a market cap of $19,914,973.20. A cluster buy pattern is present with 3 other insiders also purchasing within the past 14 days, though this does not indicate coordinated action by the CEO himself. The persistence of insider buying amid deteriorating fundamentals and the insider's historical poor 90-day outcomes at this ticker warrant detailed examination of the underlying strategic rationale.

Ence Chuck bought 228,961 shares of RLMD at $0.45 on 2025-05-16; stock now $0.60, -86.2% from 52-week high of $4.36.

Ence Chuck purchased 228,961 shares at $0.45, expanding his holdings by 587.5% to 267,931 shares total, in a company with severe fundamentals: annual revenue declined 35.4%, net income was negative $17,559,465, and market cap is only $19,914,973.20. The purchase price of $0.45 is well below the 52-week high of $4.36 (-86.2%), though the stock has rebounded 107.0% over the past 30 days and 82.9% over 90 days. His same-ticker buy history at RLMD shows mixed timing: of his 3 prior purchases at this ticker, only 1 of 3 registered positive 90-day returns (33.3% well-timed rate), with results ranging from +68.1% to -10.2% at the 90-day mark. A cluster pattern emerged with 3 other insiders also buying within the past 14 days, though this reflects coordinated rather than sole conviction.